At Maman Biomedical, we’re transforming how hormones and specialty drugs are delivered—making treatments less painful, less wasteful, and more accessible. Today, many therapies require repeated injections, high doses, and processes that leave patients physically and emotionally drained. By eliminating the need for needles and delivering medications in a more stable, sustained way, we reduce both the trauma of treatment and the burden on the body. This opens the door for patients who might otherwise avoid or be excluded from care—whether due to medical limitations, anxiety, or lack of resources. Our first focus is on fertility care, where In Vitro Fertilization (IVF) can mean 20+ injections in less than two weeks. But our platform has the potential to reshape drug delivery across a range of hormonal and specialty therapies. Our platform includes: 1. Maman Port — a plug-and-play microneedle device for liquid injectables that replaces multiple daily injections. 2. Maman Patch — a dissolving microneedle patch for sustained hormone release and real-time monitoring. 3. Maman Sense — a companion biosensor and app ecosystem for personalized, data-driven care. And because healthcare innovation should not come at the planet’s expense, we are embedding sustainability into every stage of development—using greener packaging, exploring bio-based materials, and balancing environmental responsibility with patient safety. We’re building a more compassionate, inclusive, and sustainable path to drug delivery. No more needles. Our pre-seed tranche 1 is open now, to both accredited and non-accredited investors: https://portal.equivesto.com/offering/maman#overview
Something looks off?